Premium
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane
Author(s) -
Bernitsas Evanthia,
Wei Wei,
Mikol Daniel D.
Publication year - 2006
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20747
Subject(s) - mitoxantrone , dexrazoxane , cardiotoxicity , medicine , multiple sclerosis , oncology , pharmacology , chemotherapy , cancer , breast cancer , immunology , anthracycline
Objective To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. Methods An open‐label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48mg/m 2 cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography. Results No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, −3.80% vs −8.55%, p < 0.001). Interpretation These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients. Ann Neurol 2006;59:206–209